{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:05:02Z","timestamp":1789110302343,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Locally advanced periorbital cutaneous squamous cell carcinoma (cSCC) may require orbital exenteration, which is highly morbid. As immunotherapy develops, orbit preservation may become widespread, and data benchmarking survival with current standard-of-care surgery and radiotherapy are essential to the integration of this emerging method into modern treatment paradigms. This study aimed to determine the survival of patients after orbital exenteration for cSCC and investigate contributing factors. It was hypothesized that postoperative radiotherapy would be associated with improved survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a retrospective cohort study of patients with T3 and T4 cSCC undergoing orbital exenteration. Survival analysis was performed using Cox proportional hazards.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study enrolled 40 patients with a median age of 61.5 years who met the criteria. None of the patients had received preoperative radiotherapy. Age (hazard ratio [HR], 1.09; <jats:italic>p<\/jats:italic> = 0.019) and residual disease (HR, 9.00; <jats:italic>p<\/jats:italic> = 0.003) were associated with worse survival. Postoperative radiotherapy (HR, 0.003; <jats:italic>p<\/jats:italic> &lt; 0.001) was associated with improved survival. Perineural, lymphovascular, and bony invasion and T and N stage were not associated with survival. Survival with postoperative radiotherapy was 94 % at 1 year, 87 % at 2 years, and 84 % at 5 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The oncologic outcomes of orbital exenteration with postoperative radiotherapy for locally advanced head and neck cSCC are good. However, amelioration of the morbidity caused by resection of the eye would be ideal. Data to support immunotherapy as a sole therapy are currently limited, but a combination of neoadjuvant immunotherapy and surgical treatment may facilitate orbit-preserving treatment in the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-024-16854-w","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:16:53Z","timestamp":1736803013000},"page":"2725-2731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival After Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma: A Retrospective Cohort Study"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0974-9224","authenticated-orcid":false,"given":"Alexander","family":"Murray-Douglass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G. M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"16854_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/s0190-9622(08)81509-5","volume":"30","author":"DL Miller","year":"1994","unstructured":"Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30:774\u20138. https:\/\/doi.org\/10.1016\/s0190-9622(08)81509-5.","journal-title":"J Am Acad Dermatol."},{"key":"16854_CR2","doi-asserted-by":"publisher","unstructured":"Olsen CM, Pandeya N, Green AC, Ragaini BS, Venn AJ, Whiteman DC. Keratinocyte cancer incidence in Australia: a review of population-based incidence trends and estimates of lifetime risk. Public Health Res Pract. 2022;32 20220310. https:\/\/doi.org\/10.17061\/phrp3212203.","DOI":"10.17061\/phrp3212203"},{"key":"16854_CR3","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Foncillas J, Tejera-Vaquerizo A, Sanmart\u00edn O, et al. Update on management recommendations for advanced cutaneous squamous cell carcinoma. Cancers Basel. 2022;14 20220127. https:\/\/doi.org\/10.3390\/cancers14030629.","DOI":"10.3390\/cancers14030629"},{"key":"16854_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/s1011-1344(01)00198-1","volume":"63","author":"BK Armstrong","year":"2001","unstructured":"Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63:8\u201318. https:\/\/doi.org\/10.1016\/s1011-1344(01)00198-1.","journal-title":"J Photochem Photobiol B."},{"issue":"Suppl 8","key":"16854_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jdv.15967","volume":"33","author":"A Stang","year":"2019","unstructured":"Stang A, Khil L, Kaj\u00fcter H, et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. J Eur Acad Dermatol Venereol. 2019;33(Suppl 8):6\u201310. https:\/\/doi.org\/10.1111\/jdv.15967.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"16854_CR6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/dss.0000000000002117","volume":"46","author":"R Tripathi","year":"2020","unstructured":"Tripathi R, Knusel KD, Ezaldein HH, Bordeaux JS, Scott JF. Characteristics of patients hospitalized for cutaneous squamous cell carcinoma. Dermatol Surg. 2020;46:742\u20136. https:\/\/doi.org\/10.1097\/dss.0000000000002117.","journal-title":"Dermatol Surg."},{"key":"16854_CR7","doi-asserted-by":"publisher","first-page":"104443","DOI":"10.1016\/j.oraloncology.2019.104443","volume":"99","author":"L McDowell","year":"2019","unstructured":"McDowell L, Yom SS. Locally advanced non-melanomatous skin cancer: contemporary radiotherapeutic management. Oral Oncol. 2019;99:104443. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104443.","journal-title":"Oral Oncol."},{"key":"16854_CR8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.eye.6702380","volume":"20","author":"AG Tyers","year":"2006","unstructured":"Tyers AG. Orbital exenteration for invasive skin tumours. Eye Lond. 2006;20:1165\u201370. https:\/\/doi.org\/10.1038\/sj.eye.6702380.","journal-title":"Eye Lond."},{"issue":"435\u201340","key":"16854_CR9","doi-asserted-by":"publisher","first-page":"20110210","DOI":"10.1111\/j.1755-3768.2010.02092.x","volume":"90","author":"ML Rasmussen","year":"2012","unstructured":"Rasmussen ML, Ekholm O, Prause JU, Toft PB. Quality of life of eye amputated patients. Acta Ophthalmol. 2012;90(435\u201340):20110210. https:\/\/doi.org\/10.1111\/j.1755-3768.2010.02092.x.","journal-title":"Acta Ophthalmol."},{"issue":"765\u201376","key":"16854_CR10","doi-asserted-by":"publisher","first-page":"20150508","DOI":"10.1586\/14737140.2015.1042865","volume":"15","author":"Y Rong","year":"2015","unstructured":"Rong Y, Zuo L, Shang L, Bazan JG. Radiotherapy treatment for nonmelanoma skin cancer. Expert Rev Anticancer Ther. 2015;15(765\u201376):20150508. https:\/\/doi.org\/10.1586\/14737140.2015.1042865.","journal-title":"Expert Rev Anticancer Ther."},{"issue":"294\u2013305","key":"16854_CR11","doi-asserted-by":"publisher","first-page":"20200114","DOI":"10.1016\/s1470-2045(19)30728-4","volume":"21","author":"MR Migden","year":"2020","unstructured":"Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(294\u2013305):20200114. https:\/\/doi.org\/10.1016\/s1470-2045(19)30728-4.","journal-title":"Lancet Oncol."},{"issue":"1276\u201385","key":"16854_CR12","doi-asserted-by":"publisher","first-page":"20210720","DOI":"10.1016\/j.annonc.2021.07.008","volume":"32","author":"BGM Hughes","year":"2021","unstructured":"Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32(1276\u201385):20210720. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.008.","journal-title":"Ann Oncol."},{"issue":"1557\u201368","key":"16854_CR13","doi-asserted-by":"publisher","first-page":"20220912","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(1557\u201368):20220912. https:\/\/doi.org\/10.1056\/NEJMoa2209813.","journal-title":"N Engl J Med."},{"key":"16854_CR14","doi-asserted-by":"publisher","first-page":"9514","DOI":"10.1200\/JCO.2024.42.16_suppl.9514","volume":"42","author":"R Ladwa","year":"2024","unstructured":"Ladwa R, Lee JHJ, Porceddu SV, et al. A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. J Clin Oncol. 2024;42:9514\u20139514. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9514.","journal-title":"J Clin Oncol."},{"key":"16854_CR15","doi-asserted-by":"publisher","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370: 1453\u20131457. 2007\/12\/08. https:\/\/doi.org\/10.1016\/s0140-6736(07)61602-x.","DOI":"10.1016\/s0140-6736(07)61602-x"},{"key":"16854_CR16","doi-asserted-by":"publisher","unstructured":"Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64:1051\u20139. 2011\/01\/20. https:\/\/doi.org\/10.1016\/j.jaad.2010.08.033.","DOI":"10.1016\/j.jaad.2010.08.033"},{"key":"16854_CR17","doi-asserted-by":"publisher","unstructured":"Amin MB, Greene FL, Edge SB, et al. The eighth-edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67:93\u20139. 2017\/01\/18. https:\/\/doi.org\/10.3322\/caac.21388.","DOI":"10.3322\/caac.21388"},{"key":"16854_CR18","unstructured":"StataCorp. Stata Statistical Software: Release 16. StataCorp LLC, College Station, TX, 2019."},{"issue":"379\u201388","key":"16854_CR19","doi-asserted-by":"publisher","first-page":"20161021","DOI":"10.1038\/eye.2016.218","volume":"31","author":"RC Gerring","year":"2017","unstructured":"Gerring RC, Ott CT, Curry JM, Sargi ZB, Wester ST. Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival. Eye Lond. 2017;31(379\u201388):20161021. https:\/\/doi.org\/10.1038\/eye.2016.218.","journal-title":"Eye Lond."},{"key":"16854_CR20","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/bjo.2005.072892","volume":"89","author":"I Rahman","year":"2005","unstructured":"Rahman I, Maino A, Cook AE, Leatherbarrow B. Mortality following exenteration for malignant tumours of the orbit. Br J Ophthalmol. 2005;89:1445\u20138. https:\/\/doi.org\/10.1136\/bjo.2005.072892.","journal-title":"Br J Ophthalmol."},{"key":"16854_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1034\/j.1600-0420.1999.770316.x","volume":"77","author":"F Mouriaux","year":"1999","unstructured":"Mouriaux F, Martinot V, Pellerin P, Patenotre P, Rouland JF, Constantinides G. Survival after malignant tumors of the orbit and periorbit treated by exenteration. Acta Ophthalmol Scand. 1999;77:326\u201330. https:\/\/doi.org\/10.1034\/j.1600-0420.1999.770316.x.","journal-title":"Acta Ophthalmol Scand."},{"issue":"631\u201343","key":"16854_CR22","doi-asserted-by":"publisher","first-page":"20150928","DOI":"10.1016\/j.joms.2015.09.019","volume":"74","author":"GR Hoffman","year":"2016","unstructured":"Hoffman GR, Jefferson ND, Reid CB, Eisenberg RL. Orbital exenteration to manage infiltrative sinonasal, orbital adnexal, and cutaneous malignancies provides acceptable survival outcomes: an institutional review, literature review, and meta-analysis. J Oral Maxillofac Surg. 2016;74(631\u201343):20150928. https:\/\/doi.org\/10.1016\/j.joms.2015.09.019.","journal-title":"J Oral Maxillofac Surg."},{"issue":"949\u201355","key":"16854_CR23","doi-asserted-by":"publisher","first-page":"20190515","DOI":"10.1177\/0003489419848786","volume":"128","author":"CB Sullivan","year":"2019","unstructured":"Sullivan CB, Andresen NS, Kendell N, Al-Qurayshi Z, Pagedar NA. Survival outcomes for advanced cutaneous squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2019;128(949\u201355):20190515. https:\/\/doi.org\/10.1177\/0003489419848786.","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"16854_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/archotol.124.6.637","volume":"124","author":"JJ Fagan","year":"1998","unstructured":"Fagan JJ, Collins B, Barnes L, D\u2019Amico F, Myers EN, Johnson JT. Perineural invasion in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124:637\u201340. https:\/\/doi.org\/10.1001\/archotol.124.6.637.","journal-title":"Arch Otolaryngol Head Neck Surg."},{"issue":"875\u201384","key":"16854_CR25","doi-asserted-by":"publisher","first-page":"20221118","DOI":"10.1038\/s41433-022-02306-w","volume":"37","author":"JY Tong","year":"2023","unstructured":"Tong JY, Huilgol SC, James C, Rajak S, Selva D. Perineural invasion and perineural spread in periocular squamous cell carcinoma. Eye Lond. 2023;37(875\u201384):20221118. https:\/\/doi.org\/10.1038\/s41433-022-02306-w.","journal-title":"Eye Lond."},{"key":"16854_CR26","first-page":"527","volume":"53","author":"M McLean","year":"2011","unstructured":"McLean M. Adapting to loss of an eye. B C Med J. 2011;53:527.","journal-title":"B C Med J."},{"key":"16854_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/injuryprev-2019-043286","volume":"26","author":"LJ Spencer","year":"2020","unstructured":"Spencer LJ, Lydia RL, Catherine B, et al. The global burden of falls: global, regional, and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017. Injury Prev. 2020;26:i3. https:\/\/doi.org\/10.1136\/injuryprev-2019-043286.","journal-title":"Injury Prev."},{"issue":"12","key":"16854_CR28","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41433-022-02358-y","volume":"37","author":"A Tiosano","year":"2023","unstructured":"Tiosano A, Ben-Ishai M, Cnaany Y, et al. Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration. Eye Lond. 2023;37(12):2482\u20137. https:\/\/doi.org\/10.1038\/s41433-022-02358-y.","journal-title":"Eye Lond."},{"key":"16854_CR29","doi-asserted-by":"publisher","unstructured":"Migden MR, Schmults CD, Khushalani NI, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2, and 3. SKIN J Cutaneous Med. 2023;7:s176. https:\/\/doi.org\/10.25251\/skin.7.supp.176.","DOI":"10.25251\/skin.7.supp.176"},{"key":"16854_CR30","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaophthalmol.2022.3919","volume":"140","author":"KS Park","year":"2022","unstructured":"Park KS, Guo T, Liu CY. Cutaneous squamous cell carcinoma with orbital extension. JAMA Ophthal. 2022;140:1133\u20134. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3919.","journal-title":"JAMA Ophthal."},{"issue":"1196\u2013205","key":"16854_CR31","doi-asserted-by":"publisher","first-page":"20231021","DOI":"10.1016\/s1470-2045(23)00459-x","volume":"24","author":"ND Gross","year":"2023","unstructured":"Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab and surgery for stage II\u2013IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol. 2023;24(1196\u2013205):20231021. https:\/\/doi.org\/10.1016\/s1470-2045(23)00459-x.","journal-title":"Lancet Oncol."},{"issue":"4557\u201365","key":"16854_CR32","doi-asserted-by":"publisher","first-page":"20210629","DOI":"10.1158\/1078-0432.Ccr-21-0585","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Amit M, Nagarajan P, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27(4557\u201365):20210629. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0585.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16854-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16854-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16854-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:28:40Z","timestamp":1741195720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16854-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["16854"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16854-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Brett Hughes served on the advisory boards of BMS, MSD, AstraZeneca, Pfizer, Roche, Sanofi, Eisai, and Amgen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}